Atlas Trials

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

Clinical trial NCT06329401 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06329401
Sponsor
Avalyn Pharma Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Pulmonary FibrosisProgressive Pulmonary FibrosisPulmonary Fibrosis Secondary to Systemic SclerosisPulmonary Fibrosis, Interstitial Lung DiseaseInterstitial Lung DiseaseInterstitial Lung Disease Due to Connective Tissue Disease (Disorder)Interstitial Lung Disease in Patients With Rheumatoid ArthritisInterstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified ElsewhereHypersensitivity PneumonitisInterstitial Lung Disease With Systemic Sclerosis
Start date
2024-04-03
Primary completion
2027-06-01
Enrollment
375

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.